1 Introduction
Metamizole is an analgetic, antipyretic and spasmolytic drug that was patented in Germany in 1922. It has been banned from the market in the USA and the UK because of its side effects, mainly severe agranulocytosis [
1,
2]. However, it is still widely used in several countries and particularly in Germany the use has increased in recent years [
3]. Yet, despite its use over several decades, only a few reports on liver damage caused by metamizole have been published until recently [
4]. In the drug label in Germany, neither the deterioration of liver function tests nor acute liver failure (ALF) is listed as an adverse event. Considering the extensive hepatic metabolism of metamizole, mainly mediated by cytochrome P450 [
5], its lipophilicity and the relatively high daily dose, all of which are known risk factors for drug-induced liver injury (DILI) [
6,
7], it is surprising that the hepatotoxic potential has not been a topic for pharmacovigilance until now. Interestingly, Sebode et al. reported 23 cases of metamizole-induced DILI recently, which corresponded to 15% of all the DILI cases included in their centre [
8]. The majority of the cases presented with a hepatocellular type of injury, nearly 50% of patients fulfilled Hy’s law criteria, meaning alanine aminotransferase (ALT) > 3 × the upper limit of normal (ULN) and total bilirubin (TBIL) > 2 × ULN, and 9% of the patients developed ALF [
8].
Drug-induced liver injury is a diagnosis of exclusion, based on ruling out other causes for liver injury [
9]. Because of the lack of specific biomarkers or diagnostic tests, adjudication of the culprit drug is based on causality assessment scores, mainly the RUCAM (Roussel Uclaf Causality Assessment Method) score and expert opinion [
6,
10]. However, relying on the RUCAM may not always be practical, as RUCAM comprises previously described DILI potential and reaction to re-exposure [
11]. Thus, especially in the setting of polypharmacy, drugs that have formerly not been known to cause DILI will not be associated with liver injury, causing a bias towards underestimation of their potential to cause liver injury. To further investigate the role and features of metamizole in DILI, we analysed the clinical characteristics of patients with suspected metamizole-induced acute liver injury and compared the distinctive features of more severe metamizole-DILI cases.
2 Methods
2.1 Patient Cohort
The data from 383 patients who were referred to the University Hospital Munich with acute liver injury and recruited for our ongoing prospective study on the effects of potentially hepatotoxic drugs (ClinicalTrials.gov: NCT 02353455) between March 2013 and July 2020 were analysed. Included in this study are healthy donors, patients prior to receiving therapy with drugs with DILI potential, patients with acute liver injury and DILI suspicion, as well as patients with acute liver injury as a result of other causes. Written informed consent was obtained from each patient. The study protocol conforms to the ethical guidelines of the Declaration of Helsinki and was approved by the Ethics Committee of the Faculty of Medicine, LMU Munich (project number 55-13). For the current analysis, 32 patients who had consumed metamizole were selected.
2.2 Definition, Diagnosis and Classification of DILI
Acute liver injury was defined according to the consensus criteria from 2011: (a) ALT ≥ 5 × ULN, (b) alkaline phosphatase activity ≥ 2 × ULN, or (c) ALT ≥ 3 × ULN and TBIL ≥ 2 × ULN [
12]. The ULN for aspartate aminotransferase (AST) activity and ALT were 35 U/L for women and 50 U/L for men, the ULN for alkaline phosphatase was 105 U/L for women and 130 U/L for men and the ULN for TBIL was 1.2 mg/dL. The type of liver injury was classified using the
R ratio values, (ALT/ULN)/(alkaline phosphatase/ULN), with
R ≥5 defining a hepatocellular injury,
R ≤ 2 a cholestatic injury and 2 <
R < 5 defining a mixed-type injury [
13].
The diagnosis of DILI was based on clinical and laboratory findings, the RUCAM score [
14], a causality assessment by the treating physician and expert opinion [
15], as well as an in vitro test established in our centre using monocyte-derived hepatocyte-like cells (MH cells) [
16‐
18]. The interpretation of the RUCAM score is: < 0, drug is excluded as the cause; 1–2, unlikely; 3–5, possible; 6–8, probable; and > 8, highly probable. Regarding the RUCAM score for metamizole, 1 point was given for the item ‘known hepatoxicity’, as liver injury is not listed as an adverse event in the drug label of metamizole but has been described in the literature [
4,
8]. A causality assessment by the treating physician was conducted and expert opinion from consulting hepatologists from our centre was used by consideration of all clinical data available, the course of events and by using the LiverTox database [
19]. The assessment of causality was performed independently from the MH cell test result.
Blood samples for MH cell testing were acquired within 4 weeks after the onset of liver injury. Monocyte-derived hepatocyte-like cell generation and testing were performed as described previously [
20]. Briefly, monocytes were isolated from patients’ blood samples and cultivated under serum-free conditions for 10 days, generating cells with some hepatocyte features such as cytochrome P450 activities. These cells, MH cells, are incubated for 48 hours in 96-well plates using 1 × maximum concentration (
Cmax) and 10 ×
Cmax of the implicated drugs the respective patient had consumed. For the current analysis, MH cell testing was performed for every patient and metamizole was tested in 94% of the patients included along with the concomitant medications used by the respective patients. Metamizole was used in concentrations of 50 µM and 500 µM, which equals 1 ×
Cmax and 10 ×
Cmax of this drug. The lowest amount of cells used for a single test is 10,000 cells per well. All drugs are solved in a standardised medium (DMEM/HAM-F12 containing penicillin/streptomycin and 2
l-glutamine). Then, toxicity is measured with a standardised algorithm based on the release of lactate dehydrogenase in the supernatant and cell lysate. Results are normalised to a negative (0%) and positive control (100%), meaning lysis with 1% TWEEN
®20 (polyethylene glycol sorbitan monolaurate). To compensate for variance in seeding density, toxicity values are divided by two standard deviations (ULN) of the individual controls. The vector graphic demonstrating MH cell test results was created using Prism 8, Version 8.4.3.
The severity of the DILI episode was categorised as mild (1), moderate (2), severe (3) or fatal (4; death or the need for liver transplantation because of liver failure) according to the 2011 criteria of an international DILI expert group [
12]. Acute liver failure was defined according to the American Association for the Study of Liver Diseases: (1) absence of pre-existing liver disease, (2) coagulopathy with an INR ≥ 1.5 in the absence of oral anticoagulants and (3) hepatic encephalopathy [
21]. ‘Hy’s law’ criteria were fulfilled if ALT was ≥ 3 × ULN and TBIL was ≥ 2 × ULN, defining a subgroup of patients with DILI with a 10% risk of fatality or need of liver transplantation [
22].
2.3 Data Collection
At enrolment, a thorough medical history was taken, including previous diseases, symptoms associated with liver injury, co-morbidities as well as current or previous medications. Each patient’s age, sex, ethnicity, height, weight and relevant data from clinical investigations were recorded. A thorough hepatological work-up, including liver function tests, serological studies for hepatitis A, B, C, D, and E, cytomegalovirus, Epstein–Barr virus and herpes simplex virus as well as autoantibody screening was performed, and results were extracted from the medical records. The presence of anti-nuclear antibodies (ANA) and other liver-specific antibodies was tested using an indirect immunofluorescence assay kit, Mosaic Basic Profile 3 (Euroimmun, Lübeck, Germany). The immunofluorescence assay was performed with an initial dilution of 1:100. In addition to serological testing, hepatitis E polymerase chain reaction was performed in 50% of the cases. Whenever a liver biopsy was conducted during the diagnostic work-up, the results were extracted from the pathological report.
2.4 Statistical Analysis
Statistical analyses were performed using SPSS, Version 26.0.0.1 (IBM, Armonk, NY, USA). After testing for normal distribution, parametric or non-parametric tests (Chi-square test, Fisher’s exact test or Mann–Whitney U test) were applied, p ≤ 0.05 was considered statistically significant.
4 Discussion
In our cohort of 238 patients with DILI, 32 patients (13 %) were diagnosed with suspected metamizole-induced liver injury. This proportion is in line with the results recently published by Sebode et al., who reported that metamizole was the implicated drug in 15% of their DILI cases [
8]. The relatively high percentage of patients using metamizole in our cohort and their DILI cohort can be explained by the growing popularity of metamizole as an analgetic in the German market [
3], which emphasises the need to further investigate its potential to cause DILI. In clinical trials, the potential of certain drugs to cause liver injury can be missed owing to the low incidence of overt DILI and therefore might only be revealed by post-marketing surveillance studies or voluntary reporting of suspected cases of liver injury [
23,
24]. A DILI diagnosis and causality assessment is challenging, especially in the case of polymedication because no reliable diagnostic test is available. Physicians need to rely on expert opinion and causality assessment tools like the RUCAM score. However, the RUCAM score might be misleading as it comprises previous information on hepatotoxicity and reaction to re-exposure of the implicated drug, which limits its efficacy in evaluating agent-causing liver injury in clinical trials and for drugs commonly not associated with DILI [
25]. Thus, the DILI potential of drugs that have not been related to DILI neither in clinical trials nor post-marketing, such as metamizole, can be underestimated. In line with this, only 38% of the patients in our cohort presented with a RUCAM score for metamizole of 6 or higher while the RUCAM score for the comedication was 6 or above in 14 (44%) cases. We therefore sought to analyse the characteristics of patients with suspected metamizole-DILI to establish a more profound clinical and pathological signature of metamizole-DILI.
Clinical characteristics with a slight female predominance, a median age at onset of 41 years as well as the mostly hepatocellular pattern of injury were comparable to those in patients with metamizole-DILI described recently [
8]. Interestingly, it could be shown by thoroughly analysing histopathological features that a relatively large proportion of patients presented with necrosis and eosinophilic cell infiltration (85% respectively).
To identify possible distinguishing features for the effectiveness of causality assessment tools in metamizole-induced DILI, we performed a subgroup analysis comparing the clinical and histopathological characteristics in patients with probable or highly probably metamizole-DILI (RUCAM ≥6) and possible metamizole-DILI (RUCAM 3–5). While ANA positivity was quite a frequent finding in all patients, lower RUCAM scores correlated with AMA positivity. The finding of relatively high ANA and AMA positivity is in line with recent data from our group demonstrating that ANA and also AMA positivity is frequently found in patients with DILI [
26]. Furthermore, cholestasis was a prominent feature in the histopathological analysis in patients with higher RUCAM scores; however, this difference did not reach statistical difference. Apart from this, no other relevant differences between patients with higher and lower RUCAM scores were identified. In conclusion, the current results indicate that both patients with RUCAM ≥ 6 or < 6 were fairly similar, which argues against the RUCAM score being a reliable discriminating tool in the assessment of metamizole-induced DILI. Thus, in addition to RUCAM, a causality assessment should be based on a variety of methods, for example, expert opinion, evolution of liver parameters after discontinuation of the drug, potential re-exposure and possibly a causality assessment toll such as MH cell testing. Especially in the case of metamizole, evaluating re-challenges could be useful, as metamizole might be prescribed again even after an episode of DILI because of the underestimation of its DILI potential. In line with this, seven out of the 32 patients from our cohort (22%) reported a mostly unintentional positive re-challenge with metamizole.
Strikingly, a high proportion of patients developed not only jaundice (66%) but also ALF (22%). When focusing on the distinctive features of more severe metamizole-induced DILI cases, the development of clinically relevant jaundice was associated with higher serum transaminases and INR levels at onset and at peak levels, longer latency from the initiation of metamizole treatment, and a more pronounced cholestasis and higher frequency of fibrosis in the histopathological analysis. Jaundiced patients were also more likely to have a more unfavourable outcome with higher proportions of patients developing ALF. Thus, a more severe evolution and possibly the development of ALF needs to be expected in the case of a latency of approximately 2–3 months from the initiation of metamizole intake as well as severely altered serum liver biochemistry.
Because metamizole has been underestimated as a causative agent in DILI, little is known about the mechanisms of metamizole-induced liver injury. The current understanding of idiosyncratic DILI is that the adaptive immune system plays an important role in the pathogenesis of the liver injury [
6,
27]. The characteristics observed in the patients with suspected metamizole-DILI, i.e., immune cell infiltration in all of the liver specimens with a predominance of eosinophilic cells as well as a high percentage of ANA positivity, indicate that immunological mechanisms might also play a pivotal role in metamizole-induced liver injury. This is in line with scarce previous data on metamizole-DILI proposing a potential immune-mediated mechanism [
28].
Our results have major implications for clinical trials as well as post-marketing pharmacovigilance. It could be demonstrated in our cohort that metamizole-induced liver injury needed to be suspected in 13% of all patients with DILI. Especially in Germany, the use of metamizole has further increased in recent years [
3], which might lead to an increase in metamizole-induced DILI cases as well. As metamizole is often taken as a concomitant analgetic medication in polymedicated patients and might also be used by patients participating in clinical trials, it can possibly cause liver injury unrelated to the study medication or other important treatments that cannot easily be replaced by alternative drugs. Because DILI is one of the major reasons for the cessation of drug development and post-marketing withdrawals [
6,
9], an adequate causality assessment is therefore crucial to avoid unnecessary project terminations [
25]. Thus, we encourage physicians treating patients with suspected DILI as well as clinical investigators to consider metamizole as a DILI-causing agent and actively ask the patient about concomitant metamizole use.
Our study has limitations, for instance, the lack of a universal gold standard for the causality assessment. For the current analysis, the DILI diagnosis and causality assessment were based on expert opinion and RUCAM scoring and were supported by MH cell testing. However, the usefulness of the RUCAM score is limited, as the RUCAM comprises the existing knowledge about the DILI potential of the respective drug. As neither ALF nor elevation of liver function tests is listed in the labelling of metamizole, an underestimation of the actual RUCAM might be possible. In addition, all of the patients had concomitant medications, mainly antibiotics and non-steroidal antirheumatic drugs, which were used in half of the cases. It cannot be fully excluded that the liver injury was caused by the concomitant medication taken by the patients from our cohort. Yet, there is a potential bias, especially regarding the causality assessment based on RUCAM, as liver injury is listed as an adverse reaction in the drug labels of most antibiotics and analgesics, which automatically increases the RUCAM score for the majority of the comedications. In line with this, the median RUCAM score for metamizole and for the concomitant drug with the highest RUCAM was 5, which shows that the RUCAM score cannot reliably discriminate metamizole among other possible causative agents of DILI in polymedicated patients. Therefore, we would like to suggest a score of two rather than one in the RUCAM score for metamizole for the item known hepatoxicity. This would automatically lead to higher RUCAM scores and therefore less underestimation of metamizole in DILI. If a score of two for known potential to cause DILI was assumed for metamizole, median RUCAM would have been 6 (4–10) in our cohort with 21 patients (66%) reaching a RUCAM of 6 or higher and 18 of those (85%) presenting with positive MH cell test results for metamizole.
A unique strength of our study is the use of an in vitro test system. While in the work of Sebode et al. the DILI diagnosis and causality assessment were solely based on RUCAM scoring [
8], in the current analysis, diagnosis was supported by the MH cell test, which can help to identify the causative drug especially in the setting of comedications. The MH cell test showed positive results for metamizole in more than 80% of patients with a RUCAM for metamizole of 6 or higher and was positive for metamizole in 70% of the DILI cases with a RUCAM of 3–5 for metamizole. Thus, while a DILI diagnosis and causality assessment solely based on RUCAM may lead to an under- or overestimation of metamizole-DILI, our results including a causality assessment tool further support the role of metamizole as a causative agent in patients with DILI. However, while the MH cell test has been validated in a cohort of patients with positive re-challenge to the respective medication with high sensitivity and specificity [
17], external validation has not been completed yet. Thus, the reliability of the MH cell tests as a causality assessment tool needs further assessment. To minimise the overestimation of metamizole-induced DILI by the MH cell test, a variety of control subjects who have been tested with this assay were included (healthy subjects, patients with metamizole intake but liver injury of an alternative cause, patients with DILI without prior metamizole treatment and patients with DILI with prior metamizole but association with a different drug). With the application of results from this collection of samples, the MH cell test would rule out metamizole-induced liver injury with a specificity of 83–94%.